PURPOSE: The purpose of this review was to determine the impact of high-dose cytarabine and asparaginase intensification, administered shortly after remission induction, on the outcome of childhood acute myeloid leukemia (AML). MATERIALS AND METHODS:Three consecutive Childrens Cancer Group (CCG) trials of acute myeloid leukemia, CCG 251 (1979 to 1983), CCG 213P (1983 to 1985), and CCG 213 (1985 to 1989) with a total of 1,294 patients, were reviewed and provide the basis of this report. RESULTS: CCG 213P demonstrated the importance of dose interval, in that two courses of cytarabine and asparaginase administered at 7-day intervals gave superior 5-year survival rates (58% v 41% from the end of induction, P < .04) to the same therapy administered at 28-day intervals. CCG 213 showed that there was no advantage to the maintenance therapy used for patients who received two courses of cytarabine and asparaginase at 7-day intervals (5-year survival, 68% [no maintenance] v 44% [maintenance] from the end of consolidation, P < .01). Inclusion of the 7-day interval cytarabine/asparaginase intensification was accompanied by an overall improvement in 5-year survival rates from diagnosis when compared with historical controls (CCG 213, 36% v CCG 251, 29%, P < .02) although other differences between these studies could also be responsible for the improvement seen. CONCLUSION: High-dose cytarabine and asparaginase intensification eliminated the benefit of prolonged maintenance therapy in childhood AML and was accompanied by an overall improvement in survival.
RCT Entities:
PURPOSE: The purpose of this review was to determine the impact of high-dose cytarabine and asparaginase intensification, administered shortly after remission induction, on the outcome of childhood acute myeloid leukemia (AML). MATERIALS AND METHODS: Three consecutive Childrens Cancer Group (CCG) trials of acute myeloid leukemia, CCG 251 (1979 to 1983), CCG 213P (1983 to 1985), and CCG 213 (1985 to 1989) with a total of 1,294 patients, were reviewed and provide the basis of this report. RESULTS:CCG 213P demonstrated the importance of dose interval, in that two courses of cytarabine and asparaginase administered at 7-day intervals gave superior 5-year survival rates (58% v 41% from the end of induction, P < .04) to the same therapy administered at 28-day intervals. CCG 213 showed that there was no advantage to the maintenance therapy used for patients who received two courses of cytarabine and asparaginase at 7-day intervals (5-year survival, 68% [no maintenance] v 44% [maintenance] from the end of consolidation, P < .01). Inclusion of the 7-day interval cytarabine/asparaginase intensification was accompanied by an overall improvement in 5-year survival rates from diagnosis when compared with historical controls (CCG 213, 36% v CCG 251, 29%, P < .02) although other differences between these studies could also be responsible for the improvement seen. CONCLUSION: High-dose cytarabine and asparaginase intensification eliminated the benefit of prolonged maintenance therapy in childhood AML and was accompanied by an overall improvement in survival.
Authors: Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio Journal: Blood Date: 2016-06-27 Impact factor: 22.113
Authors: Carol O'Hear; Hiroto Inaba; Stanley Pounds; Lei Shi; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Ching-Hon Pui; Raul C Ribeiro; Elaine Coustan-Smith; Dario Campana; Jeffrey E Rubnitz Journal: Cancer Date: 2013-09-04 Impact factor: 6.860
Authors: Laura Hinze; Maren Pfirrmann; Salmaan Karim; James Degar; Connor McGuckin; Divya Vinjamur; Joshua Sacher; Kristen E Stevenson; Donna S Neuberg; Esteban Orellana; Martin Stanulla; Richard I Gregory; Daniel E Bauer; Florence F Wagner; Kimberly Stegmaier; Alejandro Gutierrez Journal: Cancer Cell Date: 2019-04-15 Impact factor: 31.743
Authors: Caitlin W Elgarten; Andrew C Wood; Yimei Li; Todd A Alonzo; Lisa Eidenschink Brodersen; Robert B Gerbing; Kelly D Getz; Y-S Vera Huang; Michael Loken; Soheil Meshinchi; Jessica A Pollard; Lillian Sung; William G Woods; E Anders Kolb; Alan S Gamis; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2021-10-01 Impact factor: 3.167
Authors: Kris Ann P Schultz; Lu Chen; Zhengjia Chen; Toana Kawashima; Kevin C Oeffinger; William G Woods; H Stacy Nicholson; Joseph P Neglia Journal: Pediatr Blood Cancer Date: 2013-11-27 Impact factor: 3.167
Authors: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: Robert J Arceci; Bodour Salhia; Lia Gore; Timothy J Triche; Jason E Farrar; Daniel Wai; Christophe Legendre; Gerald C Gooden; Winnie S Liang; John Carpten; David Lee; Frank Alvaro; Margaret E Macy; Carola Arndt; Philip Barnette; Todd Cooper; Laura Martin; Aru Narendran; Jessica Pollard; Soheil Meshinchi; Jessica Boklan Journal: Clin Epigenetics Date: 2017-10-05 Impact factor: 6.551